Stock analysts predict that BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will report revenue of $ 442.50 million for the current quarter, according to Zack. Nine analysts provided revenue estimates for BioMarin Pharmaceutical, with estimates ranging from $ 424.00 million to $ 469.10 million. BioMarin Pharmaceutical recorded sales of $ 452.12 million in the same quarter last year, suggesting a negative growth rate of 2.1% year-over-year. The company is expected to report its next quarterly results on Thursday, February 24.
On average, analysts expect BioMarin Pharmaceutical to report annual revenue of $ 1.84 billion for the current year, with estimates ranging from $ 1.83 billion to $ 1.87 billion. of dollars. For the next fiscal year, analysts predict the company will post revenue of $ 2.08 billion, with estimates ranging from $ 1.88 billion to $ 2.23 billion. Zacks’ sales calculations are an average based on a survey of sales-side research analysts who follow BioMarin Pharmaceutical.
BioMarin Pharmaceutical (NASDAQ: BMRN) last reported its results on Tuesday, October 26. The biotech company reported ($ 0.20) earnings per share for the quarter, beating the consensus estimate of ($ 0.25) by $ 0.05. The company posted revenue of $ 408.74 million in the quarter, compared to a consensus estimate of $ 435.29 million. BioMarin Pharmaceutical recorded a return on equity of 2.02% and a net margin of 0.86%. The company’s revenue was down 14.3% year-on-year. During the same period last year, the company made a profit of $ 0.29 per share.
A number of equity analysts recently commented on the company. SVB Leerink reiterated a “buy” note on shares of BioMarin Pharmaceutical in a research note on Thursday, December 2. Oppenheimer raised its price target on BioMarin Pharmaceutical from $ 84.00 to $ 95 and assigned the company a “market performance” rating in a research note on Monday, November 22. Guggenheim raised its price target on BioMarin Pharmaceutical from $ 103.00 to $ 120.00 and assigned the company a “buy” rating in a research note on Monday, November 22. Morgan Stanley raised its price target on BioMarin Pharmaceutical from $ 82.00 to $ 90.00 and gave the company an “equal weight” rating in a research note on Monday, November 22. Finally, the Royal Bank of Canada reaffirmed a “hold” rating and issued a target price of $ 88.00 on shares of BioMarin Pharmaceutical in a research note on Tuesday, September 7. Four investment analysts rated the stock with a conservation rating and twelve issued a buy rating for the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $ 107.53.
In other news BioMarin Pharmaceutical, EVP Jeffrey Robert Ajer sold 2,739 shares of BioMarin Pharmaceutical in a transaction that took place on Tuesday, October 26. The shares were sold for an average price of $ 73.60, for a total value of $ 201,590.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Jean Jacques Bienaime sold 6,000 shares of BioMarin Pharmaceutical in a transaction that took place on Wednesday, December 15. The stock was sold at an average price of $ 82.71, for a total trade of $ 496,260.00. Disclosure of this sale can be found here. In the past three months, insiders have sold 10,239 shares of the company valued at $ 828,680. 1.69% of the shares are held by company insiders.
Institutional investors recently bought and sold shares in the company. Itau Unibanco Holding SA acquired a new position in BioMarin Pharmaceutical in the second quarter for a value of approximately $ 34,000. Ancora Advisors LLC increased its position in BioMarin Pharmaceutical by 466.7% during the 3rd quarter. Ancora Advisors LLC now owns 425 shares of the biotech company valued at $ 33,000 after purchasing 350 additional shares in the last quarter. Liberty Wealth Management LLC increased its position in BioMarin Pharmaceutical by 181.7% during the 3rd quarter. Liberty Wealth Management LLC now owns 431 shares of the biotech company valued at $ 34,000 after purchasing an additional 278 shares in the last quarter. Covington Capital Management increased its position in BioMarin Pharmaceutical by 142.7% during the 2nd quarter. Covington Capital Management now owns 500 shares of the biotech company valued at $ 42,000 after purchasing an additional 294 shares in the last quarter. Finally, Advisory Services Network LLC acquired a new position in BioMarin Pharmaceutical during the second quarter for a value of approximately $ 41,000. Hedge funds and other institutional investors hold 94.28% of the company’s shares.
Actions of BioMarin pharmaceutical stock opened for $ 88.35 on Friday. The company has a market cap of $ 16.22 billion, a PE ratio of 1,104.38, a P / E / G ratio of 9.63 and a beta of 0.49. BioMarin Pharmaceutical has a one-year low at $ 71.59 and a one-year high at $ 92.20. The company has a 50-day moving average of $ 84.80 and a 200-day moving average of $ 81.07. The company has a debt to equity ratio of 0.25, a current ratio of 4.49, and a rapid ratio of 3.03.
Profile of the pharmaceutical company BioMarin
BioMarin Pharmaceutical, Inc is committed to the development and commercialization of therapies for people with rare diseases and serious and life-threatening medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide and BMN 307. The company was founded by John C. Klock, Christopher M.
Recommended story: exceptional actions
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in BioMarin Pharmaceutical now?
Before you consider BioMarin Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold … and BioMarin Pharmaceutical was not on the list.
Although BioMarin Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here